Grifols (NASDAQ:GRFS) Lowered to Hold Rating by Zacks Research

Zacks Research downgraded shares of Grifols (NASDAQ:GRFS) from a strong-buy rating to a hold rating in a research report sent to investors on Thursday morning,Zacks.com reports.

A number of other research analysts have also weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th. Wall Street Zen cut Grifols from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 11th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Grifols in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.30.

Grifols Stock Up 1.0%

GRFS traded up $0.08 during midday trading on Thursday, reaching $8.44. The company’s stock had a trading volume of 1,326,688 shares, compared to its average volume of 889,538. Grifols has a 1 year low of $6.19 and a 1 year high of $11.14. The stock’s 50-day moving average is $9.61 and its 200-day moving average is $9.22. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of 40.19, a PEG ratio of 0.32 and a beta of 0.69. The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20.

Institutional Investors Weigh In On Grifols

Several large investors have recently bought and sold shares of GRFS. Syon Capital LLC lifted its stake in Grifols by 6.2% during the 3rd quarter. Syon Capital LLC now owns 42,927 shares of the biotechnology company’s stock valued at $428,000 after acquiring an additional 2,497 shares during the period. JPMorgan Chase & Co. boosted its holdings in Grifols by 31.8% in the third quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock worth $24,783,000 after purchasing an additional 600,118 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Grifols by 109.8% in the third quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 4,518 shares during the last quarter. AdvisorShares Investments LLC bought a new stake in Grifols in the 3rd quarter worth approximately $1,012,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Grifols during the 3rd quarter valued at $361,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.